From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis

T. Bieber is/was speaker and/or consultant for AbbVie, Aclaris, Almirall, AnaptysBio, Apogee, Aristea, Attovia, Belenos, Biocryst, Biogeneration, BioVerSys, Bluefine, Böhringer-Ingelheim, Bristol-Myers Squibb, BYOME Labs, Cantargia, CellDex, Choate, Dermavant, DirigentBio, Domain Therapeutics, EMD Serono, EngImmune, Ennovate, Evommune, Forbion, Formycon, Galderma, Gilead, GSK, ImagGeneBio, Janssen, Kyowa/Kirin, Kymera, LEO, LG Chem, Lilly, Mabylon, MSD, Micreos, Nektar, Nextech, Novartis, Numab, Ornavi, Overtone, Pfizer, Pierre Fabre, Protagonist Tx, Samsung Bioepis, Sanofi/Regeneron, Scienta Lab, Serono, SwitchKine, TIRmed, Triton Therapeutics, Triveni, UCB, Union Therapeutics, UPStream Bio, WinWard, YUHAN, Zurabio. He is founder and chairman of the board of the non-profit biotech “Davos Biosciences AG” within the international Kühne-Foundation. He is also the founder and senior medical advisor of the consulting firm “Bieber Dermatology Consulting”. F. L is/was speaker and/or consultant for Abbvie, Almirall, Amgen, Biogen, Boehringer Inglheim, Bristol-Myers-Squibb, Janssen, Johnson & Johnson LEO Pharma, Lilly, Incyte, Novartis, Roche, Sanofi, Regeneron, UCB, Union Therapeutics, Hexal, Biogen. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.